Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination regimen of three broad-spectrum beta-lactam antibiotics, each with distinct but overlapping spectra of activity. - **Meropenem** is a carbapenem antibiotic with very broad-spectrum activity against gram-positive, gram-negative, and anaerobic bacteria. It is highly effective against many resistant organisms, including extended-spectrum beta-lactamase (ESBL) producers and Pseudomonas aeruginosa[4][6]. - **Piperacillin-tazobactam** combines an antipseudomonal penicillin with the beta-lactamase inhibitor tazobactam to extend its spectrum to include many beta-lactamase-producing organisms and anaerobes[3][6]. - **Ticarcillin-clavulanate** pairs another antipseudomonal penicillin with clavulanic acid, also a beta-lactamase inhibitor, providing similar coverage for resistant gram-negatives and anaerobic bacteria[2][3][6]. These agents are used in severe or high-risk infections where multidrug-resistant organisms are suspected or confirmed—such as complicated intra-abdominal infections or hospital-acquired pneumonia—though their combined use together as a single regimen is not standard clinical practice due to overlapping spectra and increased risk of toxicity/resistance. Each component acts by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins; the inhibitors block destruction by bacterial beta-lactamases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on meropenem + piperacillin-tazobactam + ticarcillin-clavulanate.